NEW YORK, May 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
U.S. Skin Cancer Market
http://www.reportlinker.com/p0490652/US-Skin-Cancer-Market.html
This research service analyzes the U.S. skin cancer therapeutics market. Market drivers, restraints and challenges faced by industry participants are analyzed. Revenue forecasts for marketed and U.S. Food and Drug Administration (FDA) filed products are discussed. This research service also includes analysis for current pipeline products and clinical trials as well as strategic recommendations.
Table of Contents
Market Introduction and Segments
Disease Characteristics 12
Skin Cancer Market Segments 13
Melanoma Background 14
NonmelanomaBackground 15
BCC Background 16
SCC Background 17
Epidemiology 18
Risk Factors 19
Staging and Prognosis 20
Staging: Melanoma Skin Cancer 21
Staging: Nonmelanoma Skin Cancer 22
Survival Rates: Melanoma Skin Cancer 23
Patient Outlook
Patient Forecasts of Skin Cancer in the United States 25
Patient Forecasts of Melanoma in the United States 26
Patient Forecasts of BCC in the United States 27
Patient Forecasts of SCC in the United States 28
Industry Challenges 30
Current Therapies 32
Key Trends 34
Market Drivers and Restraints
Market Drivers and Restraints 37
Market Drivers 38
Market Restraints 39
Product Forecasts
Melanoma Market: Forecasting Assumptions 41
Intron-A: Revenue Forecast 42
Ipilimumab: Revenue Forecast 43
Pipeline Analysis
Late-Stage Melanoma Compounds: Clinical Trial Overview 45
Melanoma: U.S. Approval Timeline 46
Melanoma Market: Competitive Analysis 47
Strategic Recommendations 49
Skin Cancer Market: Conclusions 53
Decision Support Database
Total Population 55
Number of Biotechnology Companies 58
About Frost & Sullivan
Who is Frost & Sullivan 62
What Makes Us Unique 63
T.E.A.M. Methodology 64
Global Perspective 65
List of Figures
Skin Cancer Market: Patient Forecasts (U.S.), 2007-2017 25
Skin Cancer Market: Melanoma Patient Forecasts (U.S.), 2007-2017 26
Skin Cancer Market: BCC Patient Forecasts (U.S.), 2007-2017 27
Skin Cancer Market: SCC Patient Forecasts (U.S.), 2007-2017 28
Skin Cancer Market: Impact of Top Four Industry Challenges (U.S.), 2011-2017 30
Current Therapies for Melanoma (U.S.), 2010 32
Skin Cancer Market: Market Drivers Ranked in the Order of Impact (U.S.), 2011-2017 38
Skin Cancer Market: Market Restraints Ranked in the Order of Impact (U.S.), 2011-2017 39
Melanoma Market: Forecasting Assumptions (U.S.), 2011 41
Melanoma Market: Intron-A Revenue Forecasts (U.S.), 2007-2017 42
Melanoma Market: IpilimumabRevenue Forecasts (U.S.), 2007-2017 43
Melanoma Market: Clinical Trial Overview (U.S.), 2010 45
Melanoma Market: Competitive Analysis (U.S.), 2010 47
Decision Support Database: Total Population in Million (World), 2004-2014 55
Decision Support Database: Total Number of Biotechnology Companies (World), 2004-2014 58
List of Charts
Skin Cancer Market: Market Drivers and Restraints (U.S.), 2011-2017 37
Melanoma Market: Intron-A Revenue Forecasts (U.S.), 2007-2017 42
Melanoma Market: IpilimumabRevenue Forecasts (U.S.), 2007-2017 43
Melanoma Market: Approval Timeline (U.S.), 2011-2017 46
Skin Cancer Market: Key Stakeholders (U.S.), 2010 49
To order this report:
: U.S. Skin Cancer Market
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
U.S. Skin Cancer Market
http://www.reportlinker.com/p0490652/US-Skin-Cancer-Market.html
This research service analyzes the U.S. skin cancer therapeutics market. Market drivers, restraints and challenges faced by industry participants are analyzed. Revenue forecasts for marketed and U.S. Food and Drug Administration (FDA) filed products are discussed. This research service also includes analysis for current pipeline products and clinical trials as well as strategic recommendations.
Advertisement
Table of Contents
Market Introduction and Segments
Disease Characteristics 12
Skin Cancer Market Segments 13
Melanoma Background 14
NonmelanomaBackground 15
BCC Background 16
SCC Background 17
Epidemiology 18
Risk Factors 19
Staging and Prognosis 20
Staging: Melanoma Skin Cancer 21
Staging: Nonmelanoma Skin Cancer 22
Survival Rates: Melanoma Skin Cancer 23
Patient Outlook
Patient Forecasts of Skin Cancer in the United States 25
Patient Forecasts of Melanoma in the United States 26
Patient Forecasts of BCC in the United States 27
Patient Forecasts of SCC in the United States 28
Industry Challenges 30
Current Therapies 32
Key Trends 34
Market Drivers and Restraints
Market Drivers and Restraints 37
Market Drivers 38
Market Restraints 39
Product Forecasts
Melanoma Market: Forecasting Assumptions 41
Intron-A: Revenue Forecast 42
Ipilimumab: Revenue Forecast 43
Pipeline Analysis
Late-Stage Melanoma Compounds: Clinical Trial Overview 45
Melanoma: U.S. Approval Timeline 46
Melanoma Market: Competitive Analysis 47
Strategic Recommendations 49
Skin Cancer Market: Conclusions 53
Decision Support Database
Total Population 55
Number of Biotechnology Companies 58
About Frost & Sullivan
Who is Frost & Sullivan 62
What Makes Us Unique 63
T.E.A.M. Methodology 64
Global Perspective 65
List of Figures
Skin Cancer Market: Patient Forecasts (U.S.), 2007-2017 25
Skin Cancer Market: Melanoma Patient Forecasts (U.S.), 2007-2017 26
Skin Cancer Market: BCC Patient Forecasts (U.S.), 2007-2017 27
Skin Cancer Market: SCC Patient Forecasts (U.S.), 2007-2017 28
Skin Cancer Market: Impact of Top Four Industry Challenges (U.S.), 2011-2017 30
Current Therapies for Melanoma (U.S.), 2010 32
Skin Cancer Market: Market Drivers Ranked in the Order of Impact (U.S.), 2011-2017 38
Skin Cancer Market: Market Restraints Ranked in the Order of Impact (U.S.), 2011-2017 39
Melanoma Market: Forecasting Assumptions (U.S.), 2011 41
Melanoma Market: Intron-A Revenue Forecasts (U.S.), 2007-2017 42
Melanoma Market: IpilimumabRevenue Forecasts (U.S.), 2007-2017 43
Melanoma Market: Clinical Trial Overview (U.S.), 2010 45
Melanoma Market: Competitive Analysis (U.S.), 2010 47
Decision Support Database: Total Population in Million (World), 2004-2014 55
Decision Support Database: Total Number of Biotechnology Companies (World), 2004-2014 58
List of Charts
Skin Cancer Market: Market Drivers and Restraints (U.S.), 2011-2017 37
Melanoma Market: Intron-A Revenue Forecasts (U.S.), 2007-2017 42
Melanoma Market: IpilimumabRevenue Forecasts (U.S.), 2007-2017 43
Melanoma Market: Approval Timeline (U.S.), 2011-2017 46
Skin Cancer Market: Key Stakeholders (U.S.), 2010 49
To order this report:
: U.S. Skin Cancer Market
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker